The Bayer Pharma Data Science & Artificial Intelligence (DS&AI) F2F meeting in Madrid was a great event! The motto Connect, Clarify & Commit came to life as we connected during networking sessions, breakout sessions and social events. At the poster session we learned about our progress embedding a product mindset and driving operational excellence, closely collaborating with our partners across R&D. We heard presentations, took part in discussions, unconference sessions, asked questions and shared ideas, setting foundations for the growth of DS&AI beyond 2023. The use of POAPs was a definite social success and I am sure you did not miss Jesús’ enthusiasm as he gave an overview of this new tool. By promoting its use, we drive new ways of using this sustainable and effective tool, ultimately helping to innovate its use by doctors, within clinical trials, for patients and more. There were fun elements as well, like the final night, where our very own flash-mob took to the dance floor and we danced until way past midnight! All this was made possible by the org team: Anke Ebert, Larsen Schnadhorst, Kathleen Thies, Sheila Elz, Stefanie Holt-Noreiks and Claudia Vogt. They have done an excellent job coordinating the event, with the perfect balance of presentations, speakers, entertainment, and networking. Now let us make sure we continue to further the impact we have on bringing innovative medicines to our patients. Sai Jasti, Head of DS&AI https://bayer.com/poap

it was great meeting you during the DS&AI event in Madrid. I'd be happy if you get in touch with me, ☕️ if you want to drink a coffee or 💊 if you want chat about digital transformation in chemical & pharmaceutical drug development 🐶🌎🧪📸 🧘‍♀️🏔️🧑‍🍳🚐 🍱

I met Jesus during the Bayer Data Science & Artificial Intelligence, DS&AI, F2F event in Madrid in May 2023. Jesus works at Bayer AG currently as the Head of Business Disruption. If you are into Stranger Things, Breakthrough Innovations, AcceleRed, TeamRed, Science4Berlin, STEM4Health, Hackathons, Biotech, Digital Health, Startups, Entrepreneurship, Intrapreneurship, Web3, Web5, Networking For Health, Science, Technology, Pharma, Exobiology, Space, Science Fiction, Germany, Cuba, you can connect with Jesus in LinkedIn: https://www.linkedin.com/in/yeysus/ Twitter: https://twitter.com/yeysus Meetup: https://www.meetup.com/members/45080772/ Web3: yeysus.eth/.tez/.near Some of his POAPs collections in Welook.io: Bayer: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/1 Corporates: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/2 Animated: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/5 Ladies: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/8 Beautiful: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/9 Great connecting with you!

Recent focus has been on streamlining and optimizing the clinical operations system landscape. To support the initiative, our key business capabilities related to clinical operations are consolidated on one core platform: Gemstone. Gemstone is a Software as a Service provided by Veeva and contains modules of their Vault Clinical suite. Where possible the system remains as close to "out of the box" as possible to align with industry standards and to reduce the complexity for the 3 general releases provided by Veeva. eTMF, Startup, Monitoring, Site Connect, Feasibility components are already live. The latest Gemstone „Ruby“ went live over Eastern (April 23). IRIS is now retired, and Issue Management, Monitoring, and Study Risk Management and Study Training are available in Gemstone with more capabilities to come. Gemstone interfaces with over 50 systems and is closely integrated with RAVE, RAVEN, BRAVE and other systems. Gemstone provides a modern technology foundation with API capability, allowing connection via the Integration Hub, a bespoke PaaS solution with a unified data integration layer. As not all systems are as advanced, the Integration Hub provides a database facade that allows backward compatibility to cater to those legacy systems.